- Conditions
- B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
- Interventions
- Tecartus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- High-risk Large B-cell Lymphoma (LBCL)
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
- Conditions
- Relapsed/Refractory Mantle Cell Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Palo Alto, California • Santa Monica, California + 19 more
- Conditions
- Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Interventions
- Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
- Radiation · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
- Interventions
- Brexucabtagene Autoleucel
- Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 33 more
- Conditions
- B Cell Lymphoma
- Interventions
- Glofitamab, Obinutuzumab, Axi-cel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- KITE-197, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Miami, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 12
- States / cities
- Duarte, California • Stanford, California • Tampa, Florida + 8 more
- Conditions
- Relapsed/Refractory Mantle Cell Lymphoma
- Interventions
- brexucabtagene autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Duarte, California • Santa Monica, California + 20 more
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
- Interventions
- Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit, Blood pressure and pulse oximeter, Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Procedure · Biological · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- KITE-585, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more
- Conditions
- Relapsed or Refractory Large B-cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Relapsed and Refractory Multiple Myeloma
- Interventions
- anitocabtagene-autoleucel
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin
- Conditions
- Multiple Myeloma
- Interventions
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 50
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 37 more
- Conditions
- Relapsed or Refractory Large B-cell Lymphoma
- Interventions
- KITE-753, Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Relapsed and/or Refractory B-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, KITE-363, KITE-753
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 13
- States / cities
- Gilbert, Arizona • Duarte, California • Stanford, California + 10 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cyclophosphamide, Fludarabine, KITE-222
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Stanford, California • Tampa, Florida • St Louis, Missouri + 4 more
- Conditions
- Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia
- Interventions
- Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 8 more
- Conditions
- Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
- Interventions
- Anakinra, Axicabtagene Ciloleucel
- Drug
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
- Interventions
- KITE-363, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Duarte, California • Stanford, California
- Conditions
- B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation, T-Cell Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- CART-45 cells, CD45BE-HSPC
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2051
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Refractory Diffuse Large B Cell Lymphoma
- Interventions
- KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Palo Alto, California • Tampa, Florida + 2 more